2022 Pharmaceutical Manufacturing Vaccines 
Express Pharma
SEPTEMBER 13, 2024
The world massively relies on the developments that continue to take place in the pharmaceutical industry to experience an improved quality of life. As per a report by Straits Research, a market research company, the global continuous manufacturing market was valued at USD 504.25 million in 2022 and is predicted to reach USD 1,4290.95
pharmaphorum
JUNE 21, 2022
While proponents argue waiving IP on COVID-19 vaccines would better enable low- and middle-income countries to inoculate their populations, the pharma industry has called the proposals “unnecessary and harmful to innovation”. An IP waiver does not address inequitable access to COVID-19 vaccines and will put global health security at risk.”.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
OCTOBER 24, 2022
Three trade bodies representing vaccine creators and manufacturers are endorsing The Berlin Declaration framework , a proposal that outlines how the industry would reserve an allocation of real-time vaccine production for swift distribution to priority populations in lower-income countries in future pandemics.
European Pharmaceutical Review
MAY 31, 2023
The inventory position of 28 major pharmaceutical manufacturers in 2022 has been revealed in an annual report. Yet the balance sheets of the pharmaceutical manufacturers included in the report showed limited evidence of this. Inventories grew to a combined total of $150bn in 2022, the analysis showed.
pharmaphorum
DECEMBER 16, 2022
Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.
European Pharmaceutical Review
OCTOBER 27, 2022
Sectors such as research, testing, medical labs and pharmaceutical manufacturing expanded greatly during the pandemic, due to high demand for COVID-19 therapeutics. For instance, small and mid-sized biotech companies invested heavily in developing vaccines. To date, 747 novel compounds are in production.
European Pharmaceutical Review
JULY 21, 2023
A recent report from the US Food and Drug Administration (FDA) shows that while the number of new drug shortages has fallen significantly from a high of 250 in 2011 to 49 in 2022, there was an increase in new drug shortages year-on-year. What are the top three supply-related challenges facing pharmaceutical manufacturers?
Expert insights. Personalized for you.
103 
Let's personalize your content